AlphAIalphai — Financial news for AI agents
dailypolitical.comMAY 293 min read$DRTS

Alpha Tau Medical (NASDAQ:DRTS) Raised to Strong-Buy at Barclays

Barclays upgraded Alpha Tau Medical (NASDAQ:DRTS) to a “strong-buy” rating, according to Zacks.com. Other analysts cited in the article include Citigroup raising its price target to $9 (buy) and HC Wainwright setting $15 (buy). DRTS shares opened at $10.13; last reported EPS was -$0.26, missing consensus -$0.13.

Original reporting
dailypolitical.com
Published May 29, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 11:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Alpha Tau Medical (NASDAQ:DRTS) Raised to Strong-Buy at Barclays — source image
Source · dailypolitical.com
Decision brief

The 30-second read

$DRTSBullishMed
01

Why it matters

Barclays’ strong-buy upgrade and other target adjustments can re-rate near-term sentiment, but the fundamental debate remains tied to clinical progress and continued losses.

02

Market read

This is a sell-side rating catalyst for DRTS, potentially supporting momentum trading while fundamentals await next clinical/earnings catalysts.

03

What to watch

The article cites multiple prior target changes (some neutral/sell) and does not provide any new clinical outcome; traders may fade the upgrade if follow-up data or guidance is absent.

Relevance 7/10Novelty 5/10Timing: today/next session after the Barclays upgrade note

Background

Alpha Tau Medical develops targeted alpha-radiation therapies (DaRT) for solid tumors; it recently reported quarterly EPS of -$0.26, worse than the -$0.13 consensus.

Company-level read

Ticker impact

$DRTSBullishMedium confidence
Context

Barclays upgraded Alpha Tau Medical to a “strong-buy,” shifting Street expectations and potentially driving near-term sentiment/flows.

Expected impact

Likely short-term upward bias versus prior consensus, with volatility given recent negative EPS and mixed prior ratings.

Evidence & confidence

The article is explicitly about a Barclays rating upgrade plus multiple other target changes; however, it provides no new clinical or financial datapoint beyond the already-referenced May 18 earnings miss.

Market effects

Sector

Adds incremental positive read-through for targeted alpha-radiation/oncology medtech sentiment, but without new trial/regulatory data.

Regional

Limited; company is Israel-headquartered but the catalyst is US sell-side research.

Global

Low; primarily affects US-listed small-cap sentiment rather than global fundamentals.

Counterpoint

What could challenge this read

Despite the upgrade, the stock is still trading near a recent high with a history of mixed ratings and recent earnings miss, so upside may be capped if catalysts don’t follow.

Key entities

  • company
    Alpha Tau Medical

    Subject of the Barclays analyst upgrade and recent earnings reference (DRTS).

  • analyst_firm
    Barclays

    Upgraded DRTS to “strong-buy” in a Thursday research report.

Read at source← All news

Related articles

JUL 15
$DRTSMed

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.

manilatimes.net4 min
JUN 23
$DRTSMed

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.

manilatimes.net3 min
JUN 4
$DRTSMedAI 9/10

Alpha Tau And Tolmar Form Strategic Collaboration In U.S. Prostate Cancer

Alpha Tau Medical (DRTS) and Tolmar International announced a U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer. Tolmar will have exclusive U.S. commercialization rights for 20 years from first sale, with an option to expand to bladder cancer after milestones. Tolmar will invest $15m in manufacturing, add $20m equity at $11.99/share, and pay up to $161.5m in milestones; Alpha Tau will supply product at 60% of onward net sales.

rttnews.com4 min
AUG 9
$SMCIMed

Super Micro Computer Landed $60 Billion in Orders Last Quarter, but Trades at Just $30

Super Micro Computer (SMCI) said it booked over $60B in new orders in its fiscal Q4 ended June 30, lifting backlog to a record. It guided FY2026 revenue near the low end of $11B to $12.5B and gross margins at 15% to 17%. The company also plans $7B equity financing for AI server orders, noting some orders may not be firm and citing an independent review tied to export control issues.

fool.com6 min